Registration

About the

Nashville Hematology Conference

2025 Award Winner

Most Innovative Meetings 2025: Nashville Hematology Conference

The Nashville Hematology Conference brings together top national experts and community practitioners to explore the latest updates and challenges in the management of hematologic malignancies. The 3rd annual event will take place at the Country Music Hall of Fame® and Museum in Nashville, TN, from Thursday, February 18, 2027, to Saturday, February 20, 2027, and is intentionally designed to create a fun, informative, and innovative experience that meaningfully engages both academic and community clinicians.

This anticipated 2-day, CE-accredited conference equips attendees with the knowledge needed to navigate increasingly complex treatment landscapes across hematologic malignancies and manage patients throughout therapy. Attendees will examine current standards of care and evaluate how emerging data may influence treatment algorithms across a range of lymphoid and myeloid diseases.

The conference features engaging lectures on evolving standards of care, management of relapse after initial therapy, the integration of T‑cell redirecting therapies into community practice, and strategies for treating later relapse. Hot topic discussions—spanning healthcare policy, MRD in hematologic malignancies, and ongoing controversies in treatment—will be explored through a community‑focused lens.

Faculty experts will examine and debate treatment options across hematologic malignancies while keeping the unique challenges faced by community practitioners at the forefront. Throughout the conference, attendees can participate in live Q&A sessions and take advantage of numerous networking opportunities and personal discussions. The Nashville Hematology Conference is designed to provide attendees with the practical tools needed to provide the most current, evidence-based care for patients with hematologic malignancies.

About the

Nashville Hematology Conference

2025 Award Winner

Most Innovative Meetings 2025: Nashville Hematology Conference

The Nashville Hematology Conference brings together top national experts and community practitioners to explore the latest updates and challenges in the management of hematologic malignancies. The 3rd annual event will take place at the Country Music Hall of Fame® and Museum in Nashville, TN, from Thursday, February 18, 2027, to Saturday, February 20, 2027, and is intentionally designed to create a fun, informative, and innovative experience that meaningfully engages both academic and community clinicians.

This anticipated 2-day, CE-accredited conference equips attendees with the knowledge needed to navigate increasingly complex treatment landscapes across hematologic malignancies and manage patients throughout therapy. Attendees will examine current standards of care and evaluate how emerging data may influence treatment algorithms across a range of lymphoid and myeloid diseases.

The conference features engaging lectures on evolving standards of care, management of relapse after initial therapy, the integration of T‑cell redirecting therapies into community practice, and strategies for treating later relapse. Hot topic discussions—spanning healthcare policy, MRD in hematologic malignancies, and ongoing controversies in treatment—will be explored through a community‑focused lens.

Faculty experts will examine and debate treatment options across hematologic malignancies while keeping the unique challenges faced by community practitioners at the forefront. Throughout the conference, attendees can participate in live Q&A sessions and take advantage of numerous networking opportunities and personal discussions. The Nashville Hematology Conference is designed to provide attendees with the practical tools needed to provide the most current, evidence-based care for patients with hematologic malignancies.

TS-264

About NHC

2027 Learning Objectives

1. Appropriately apply evidence-based management practices across diverse treatment settings.

2. Integrate best practices regarding T-cell redirecting therapies into practice, including managing acute and long-term potential toxicities.

3. Apply up-to-date prognostic and molecular testing to inform clinical decision-making across the continuum of care.

4. Address challenges of treating hematologic malignancies in patients with unmet needs, including frail patients and disparate populations.

Target Audience

2027 Nashville Hematology Conference is intended for physicians, nurses, pharmacists, physician assistants, and other healthcare professionals who treat patients with hematologic malignancies.

Agenda Sessions

  • Benign and Pre-Malignant Hematology: Classical hematology hospital emergencies, sickle cell disease, VTE, MGUS/SMM, CHIP/CCUS, and monoclonal B-cell lymphocytosis, with practical panel discussion for community-facing care.
  • Lymphoid Malignancies: Current standards and 2027 updates in diffuse large B-cell lymphoma, Hodgkin lymphoma, indolent lymphomas, CLL, and evolving strategies in relapsed/refractory disease.
  • Myeloid Malignancies: AML, MPNs, MDS, CML, high-risk disease considerations, and common pitfalls in treatment selection, including where new molecular and prognostic information may inform care.
  • Multiple Myeloma: Frontline, early relapse, late relapse, non-T-cell-engager/CAR-T options, sequencing considerations, and debate-driven discussion of CAR-T and other treatment strategies.
  • MRD Across Hematologic Malignancies: Focused updates in AML, CLL, and multiple myeloma with multidisciplinary discussion of testing, interpretation, and practical application.
  • T-Cell Directed and Cellular Therapies: Patient identification, acute and long-term toxicity management, treatment barriers, CAR-T, bispecifics, and community implementation considerations.
  • Tools for Tomorrow’s Oncologist: Artificial intelligence as a decision tool, molecular testing and NGS report interpretation, policy updates, patient advocacy, and strategies to advance community care.
  • Engaging Formats: Poster session and welcome reception, rapid updates, interactive panels, structured debates, a keynote session, and non-CE breakfast/lunch symposia for deeper discussion of career development, lymphoid malignancies, women leaders in hematology, and myeloma sequencing.

The 2027 Nashville Hematology Conference (NHC 2027) will convene over 75 leading national experts, rising faculty, and community-based hematology clinicians for two days of CE-accredited education. Designed for practicing physicians and multidisciplinary oncology professionals, the conference addresses current standards, evolving treatment strategies, practical implementation challenges, and future directions across hematologic malignancies.

*Agenda is subject to change.

CME Conferences​

IDEOlogy Health’s 2-day CE-accredited conferences are carefully curated by top thought leaders and hosted at unique venues to create engaging and memorable learning experiences. Take a look at the upcoming conferences.

November 5-7, 2026
Austin, TX, at ACL Live at The Moody Theater

December 3-5, 2026
Nashville, TN, located at the Country Music Hall of Fame® and Museum

April 8-10, 2027
Austin, TX, at ACL Live at The Moody Theater